# Safety and Efficacy of AM712 in Patients with NAMD

> **NCT05345769** · PHASE1 · COMPLETED · sponsor: **AffaMed Therapeutics Limited** · enrollment: 21 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **BIOLOGICAL:** AM712(ASKG712)

## Key facts

- **NCT ID:** NCT05345769
- **Lead sponsor:** AffaMed Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-28
- **Primary completion:** 2024-11-04
- **Final completion:** 2024-11-04
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05345769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05345769, "Safety and Efficacy of AM712 in Patients with NAMD". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05345769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*